We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Register for streaming realtime charts, analysis tools, and prices.
| Share Name | Share Symbol | Market | Stock Type |
|---|---|---|---|
| Genincode Plc | GENI | London | Ordinary Share |
| Price Change | Price Change % | Share Price | Last Trade
|
|
|---|---|---|---|---|
| -0.50 | -6.45% | 7.25 | 09:24:39 |
| Open Price | Low Price | High Price | Close Price | Previous Close |
|---|---|---|---|---|
| 7.75 | 7.25 | 7.75 | 7.25 | 7.75 |
| Industry Sector |
|---|
| HEALTH CARE EQUIPMENT & SERVICES |
| Top Posts |
|---|
Posted at 18/1/2024 13:45 by timbo003 Yes, Investors are currently in a mind set that persuades them the next fund raise will inevitably be at lower price than the last one, irrespective of progress made by the company in question. This will revert back to the more normal paradigm (eventually) whereby successive fund raisings are conducted at higher prices to reflect positive progress, but alas, I cannot see that happening in the short term. |
Posted at 22/9/2023 10:19 by idomeneo According to Investor Meet Company: £8m required at the next raise "potentially our last funding". Breakeven mid 2025, profitability due 2026. Market cap today £9m. That might require a fair bit of haircut. |
Posted at 31/5/2022 08:36 by barbello https://www.investor |
Posted at 03/5/2022 08:17 by hedgehog 100 03/05/2022 07:02 UK Regulatory (RNS & others) GENinCode PLC Notice of Results LSE:GENI Genincode PlcNotice of results Analyst & investor presentations Oxford, UK. GENinCode Plc (AIM: GENI), the predictive genetics company focused on the prevention of cardiovascular disease, announces it will issue its preliminary results for the year ended 31 December 2021 on Tuesday, 17 May 2022. Matthew Walls, CEO, and Paul Foulger, CFO will host an in-person analyst meeting at the offices of Walbrook PR, 75 King William Street, London EC4N 7BE at 9.30am on 17 May. If you would like to attend, please contact Walbrook PR at genincode@walbrookpr The Company will also host a presentation for investors via the IMC platform at 3pm on 17 May. The presentation is open to all existing and potential shareholders. Questions can be submitted pre-event via your Investor Meet Company dashboard up until 9am the day before the meeting or at any time during the live presentation. To register for this, please use the following link: hxxps://www.investor For more information visit www.genincode.com |
Posted at 25/3/2022 17:18 by hedgehog 100 From GENI's AIM Admission Document dated 16 July 2021:"The Placing will raise approximately £17.0 million (before expenses) which is currently intended to be used, primarily, to complete the planned US launch of Cardio inCode and commercialisation." I.e. most of the IPO monies are being saved until Cardio inCode receives FDA US marketing approval, to be used for launch and commercialisation in the US (in conjunction with their partner Eversana). |
Posted at 26/1/2022 17:03 by hedgehog 100 We're probably in the close period ahead of GENI's final results for the year ending 31.12.21, which would prevent the directors from buying at the current depressed s.p.David Evans should be able to buy though, as he's no longer a director, provided he's not in possession of inside information. And interestingly, D.E. has just transferred £309K. of shares in his IIG life sciences fund into his SIPP, which is a sign that he considers IIG shareas to be undervalued at their current depressed share price. 24/01/2022 08:45 UKREG Intuitive Investments Group plc Director Dealing "Intuitive Investments Group plc (AIM:IIG), ("IIG" or the "Company"), announces that Mr David Evans, Executive Chairman of Intuitive Investment Group, has transferred 1,742,000 ordinary shares of 1p each in the Company ("Ordinary Shares") from a nominee account to his SIPP. The Ordinary Shares were transferred at a price of 17.75p and remain beneficially owned by Mr Evans. Accordingly, Mr Evans's total holding in the Company remains unchanged at 5,000,000 Ordinary Shares, representing approximately 12.37 per cent. of the Company's issued share capital." Intuitive Investments (IIG): |
Posted at 13/1/2022 15:20 by hedgehog 100 RENX dual-listed in the US in the summer of 2020, floating at the equivalent of over 4 times its AIM IPO price only 20 months before.This could be the 'template' for GENI. Which could equate to GENI dual-listing in the US early next year, at about 200p/share equivalent. 18/05/2020 06:00 UK Regulatory (RNS & others) Renalytix AI PLC Proposed dual-listing on Nasdaq LSE:RENX Renalytix Plc "Renalytix AI plc (LSE : RENX ), a commercial-stage artificial intelligence-enabled in vitro diagnostics company, focused on optimizing clinical management of kidney disease to drive improved patient outcomes and lower healthcare costs , announces that it has confidentially submitted a draft registration statement on Form F-1 with the Securities and Exchange Commission (the "SEC") relating to a proposed dual-listing and public offering of American Depositary Shares, each of which will represent one or a number of the Company's ordinary shares, on the Nasdaq Stock Market (the "Offering"). The number of securities to be offered and the price for the proposed Offering have not yet been determined. The Offering is expected to commence after the SEC completes its review process, subject to market and other conditions . Shareholders and potential investors should note that the potential Offering may or may not proceed." 25/06/2020 06:00 UK Regulatory (RNS & others) Renalytix AI PLC Public filing re. Nasdaq dual-listing and offering LSE:RENX Renalytix Plc 13/07/2020 11:01 UK Regulatory (RNS & others) Renalytix AI PLC Launch of Global Offering and application to list LSE:RENX Renalytix Plc 21/07/2020 16:30 UK Regulatory (RNS & others) Renalytix AI PLC Closing of Global Offering and resulting TVR LSE:RENX Renalytix Plc "Renalytix AI plc (LSE : RENX) (NASDAQ: RNLX) ("RenalytixAI" or the "Company"), an artificial intelligence -enabled in vitro diagnostics company, focused on optimizing clinical management of kidney disease to drive improved patient outcomes and lower healthcare costs , today announces the closing of its global offering of an aggregate of 11,000,000 new ordinary shares, including 5,485,000 American Depositary Shares ("ADSs") at a price of US$13.50 per ADS and 30,000 ordinary shares at a price of GBP5.37 per ordinary share (at an exchange rate of GBP:USD 1:1.2563), for aggregate gross proceeds of approximately US$74.3 million, before deducting underwriting discounts and commissions and estimated offering expenses payable by RenalytixAI. Each ADS offered represents two ordinary shares of the Company. The ADSs were offered in a registered public offering in the United States and the Company's ordinary shares were offered in a concurrent private placement in Europe and other countries outside of the United States (together, the "Global Offering"). In addition, RenalytixAI has granted the underwriters a 30-day option to purchase up to an additional 822,750 ADSs at the initial offering price per ADS less underwriting discounts and commissions. The ADSs began trading on the Nasdaq Global Market under the symbol "RNLX" on 17 July 2020. RenalytixAI's ordinary shares are admitted to trading on the AIM market of London Stock Exchange plc ("AIM") under the symbol "RENX". Application has been made for the new ordinary shares issued in Global Offering to be admitted to trading on AIM and it is expected that admission will become effective and dealings in the new ordinary shares will commence at 8:00 a.m. (BST) on 22 July 2020. J.P. Morgan and Stifel acted as joint global coordinators and joint book-running managers for the Global Offering. ..." |
Posted at 08/12/2021 21:29 by diversification He is locked-in for 12 months. So no new immediate supply of stock from William Rhodes. In fact approx 81.5% of shareholder register are locked in or long term investors.News is on the horizon at which point we should see a considerable squeeze with a low supply of stock beyond the most recent seller who will at some point be out of stock as they don’t have a declarable position. 50% of market cap unpinned by cash, crazy! But a fantastic opportunity. |
Posted at 30/11/2021 17:05 by hedgehog 100 I don't think it's likely that he would try to sell an institutional-sized stake on the market: more likely he would place it, especially with his contacts.But he's a specialist investor in this sector, so he will know how good GENI is: He's also extremely wealthy. So I think it's far more likely that he's become aware of a periodic seller of GENI shares, and wishes to take advantage of that. |
Posted at 28/10/2021 17:29 by hedgehog 100 The fact that GENI is a spin-out is a major bull point, as spin-outs on average greatly outperform the market as a whole. -"Mar 5, 2019,10:38am EST|4,108 views Spin-Offs Outperforming The Market This Year Joe Cornell Contributor Markets You can beat the Street. At a time when many professional investors lament that the proliferation of ETFs and widespread use of screening techniques have made it harder to find bargains in the stock market, one simple investing approach continues to outperform: spin-offs. Spin-offs have long been a fruitful investment area; a number of academic studies show that they historically have generated far better returns than the overall stock market. A spin-off occurs when a corporation issues stock in a subsidiary to its shareholders to create a new public company. A related corporate event is an IPO carve-out, through which a company sells the public a stake in a unit, while retaining the rest of the division. (Sometimes, the remainder is later distributed to shareholders). The Bloomberg U.S. Spin-Off Index, composed of companies spun off from larger companies within the past three years, has outperformed the broader market by nine percentage points since the start of the year through Tuesday (February 26th). The 35 member index contains equities with a value over $1 billion that were spun-off from U.S. companies. ..." |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions
Hot Features
Premium
